HPV E2/E6 Antibody Detection and Checkpoint Therapy for Abnormal Cell Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prophylactic HPV vaccines are ineffective against established HPV infections, and there is a need for improved methods to treat or prevent HPV-related diseases.
Innovation Solution
The use of HPV proteins, such as E2 and E6, for detecting infections, administering specific binding agents or antibodies, and combining with immune-checkpoint inhibitors like anti-CTLA4 and anti-PD1/PD-L1 antibodies for treating or preventing HPV-related conditions, including cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prophylactic HPV vaccines are used, then prevention of HPV infection is improved, but treatment of established HPV infection is not effective
Solution Approach 1:
The patent divides the HPV vaccine approach into two distinct segments: prophylactic vaccines for prevention and therapeutic vaccines for treatment of established infections. The therapeutic vaccine comprises HPV antigens (E6, E7, L1, L2) combined with immune stimulatory components, creating a specialized formulation that elicits both humoral and cellular immune responses specifically tailored for treating existing infections rather than just preventing new ones.
Solution Approach 2:
The patent changes the immunological parameters of the vaccine by incorporating immune stimulatory adjuvants (such as CpG oligonucleotides, alum, or MF59) and selecting specific HPV antigen combinations. These parameter changes transform the vaccine from a purely preventive tool to one that can actively treat established infections by boosting the immune system's ability to recognize and eliminate HPV-infected cells through enhanced T-cell and antibody responses.
2Measurement precision
If HPV E6 and E7 specific T cells are used in clinical trials, then targeted immune response is improved, but overall treatment efficacy remains insufficient
Solution Approach 1:
The patent merges multiple immune response mechanisms into a single therapeutic vaccine formulation. It combines humoral immunity (antibody production against L1 and L2 viral capsid proteins) with cellular immunity (T-cell activation against E6 and E7 oncoproteins) by including all four HPV antigens in one vaccine. This merging creates a comprehensive immune response that addresses both the structural viral components and the transforming oncoproteins, thereby improving overall treatment effectiveness beyond what T-cell therapy alone achieves.
Solution Approach 2:
The therapeutic vaccine is designed with multi-functionality to address different aspects of HPV pathogenesis simultaneously. The inclusion of E6 and E7 antigens targets cellular transformation and immortalization, while L1 and L2 antigens target viral assembly and infection. The vaccine also incorporates multiple immune stimulatory pathways (TLR9 activation by CpG, alum adjuvant, or MF59 emulsion) to engage both B-cell and T-cell responses, creating a universal therapeutic approach that can handle various stages and types of HPV infections.
Data Source
AI summary
This disclosure relates to HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth. In certain embodiments, this disclosure relates to detecting an HPV protein in a sample and correlating the presence as an indication that a subject is at risk of developing an HPV-related disease or condition. In certain embodiments, the HPV protein is E2 and/or E6. In certain embodiments, this disclosure relates to vaccinating or treating a subject for an HPV infection or related condition optionally in combination with immune-checkpoint inhibitors. In certain embodiments, this disclosure relates to HPV protein specific antibodies and binding agents for uses reported herein.